Navigation Links
Cord Blood America Announces 2013 Third Quarter Financial Results
Date:11/14/2013

o historical levels has been put in place."

For the three months ended September 30, 2013, total revenue decreased to approximately $1.49 million from $1.51 million, a decrease of 2% over the same period of 2012.  Recurring revenue increased approximately 8% from the year ago period.

For the period ending September 30, 2013, the company had $0.60 million in cash, an increase of 61% from $0.39 million at December 31, 2012. The Company currently collects cash receipts from operations through Cord and  BioCells. During the nine month period ended September 30, 2013 there was no increase in notes payable for purposes of working capital or investment in affiliate companies and represents six consecutive quarters without receiving any external financing. Net cash provided by operating activities for the nine month period ending September 30, 2013 was $0.33 million, versus a net use of cash of $0.23 million from the prior comparative period of 2012, an improvement of $0.60 million or 247%. Net cash used in investing activities decreased by $0.13 million. Net cash provided by financing activities decreased $0.43 million from the prior comparative period ending September 30, 2012. The Company did not have any financing activities during the nine month period ending September 30, 2013, and cash flow from operations continue to be sufficient to fund operations.

About Cord Blood AmericaCord Blood America, Inc. is the parent company of CorCell, Companies, Inc. which, along with Cord Blood America, Inc., facilitates umbilical cord blood and cord tissue stem cell processing and storage for expectant parents and their children.  Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. and CorCell Companies, Inc., visit our websites
'/>"/>

SOURCE Cord Blood America, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FindTheBest Helps Parents Find Cord Blood Banks
2. Cord Blood America Announces DTCC Removes "Chill" Imposed in December 2010
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
4. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
5. Study finds chronic abnormal brain blood flow in Gulf War veterans
6. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
7. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
8. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
9. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
10. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
11. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal Products ... by Buffalo BioBlower Technologies LLC ("B3") as the critical ... 2 award from the Army Corps of Engineers.  B3 ... kills all biological contaminants and destroys VOCs and other ...
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health , ... change technology, today announces that EmblemHealth , the ... wellness company, is now providing the RedBrick Compass health ... program, to all of its members. EmblemHealth is among ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... - Two Milestones Reached in Zonisamide Patent Portfolio ... Therapeutics,Inc. (Nasdaq: OREX ), a biopharmaceutical company ... nervous system-related disorders, today,announced the initiation of its ... formulation of zonisamide plus olanzapine.,The Phase 2a clinical ...
... 2 Clarient, Inc.,(Nasdaq: CLRT ), a ... pathologists, oncologists and the pharmaceutical industry,today announced that ... an,exclusive interview on WallSt.net,s 3-Minute Press Show., ... company, and the,significance of the company,s latest press ...
... Zevalin only Radioimmunotherapy in U.S. to be Indicated ... for Use ... Inc. (CTI),(Nasdaq and MTA: CTIC) announced today that it has ... and Drug,Administration (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as,consolidation ...
Cached Biology Technology:Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 2Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 3Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 4[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute Press Show 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5
(Date:4/23/2014)... Valley, NY. (Apr. 23, 2014) People who have ... potential to restore neurological function. However, a study conducted ... issue of Cell Transplantation , but is currently ... http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one group ... cells (PBSCs) injected directly into the brain and a ...
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... term for novels and films which focus on the consequences ... how these fictions serve as a mental laboratory that allows ... imagine other living conditions. , "Global warming is much ... is also a cultural phenomenon in which meaning is being ... see. And there are so many of them now that ...
Breaking Biology News(10 mins):Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... may begin in the womb, researchers from Tel Aviv University ... twin can compromise the health of his twin sister before ... published in the journal Pediatrics, the researchers analyzed the incidence ... twins. When born premature, girls who share the womb with ...
... A recent University of Iowa study reveals a biological link ... women than men are diagnosed with chronic pain and fatigue ... mice, the researchers, led by Kathleen Sluka, Ph.D., professor in ... the UI Roy J. and Lucille A. Carver College of ...
... 2008 The Global Innovation Imperatives (Gii) project ... their first session at the American Chemical Societys ... a joint collaboration between the ACS Committee on ... seeks to combat worldwide health, environmental and societal ...
Cached Biology News:War between the sexes begins before twins' birth, TAU researchers say 2U. Iowa study finds biological link between pain and fatigue 2At ACS' national meeting, global initiative set to tackle water issues 2
Request Info...
... blotted protein on PVDF membrane or with ... N-terminal sequence of proteins (5-20 residues) can ... HPLC or mono-and bidimensional SDS-PAGE, followed by ... the well known EDMAN degradation method. Pre-treatment ...
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
... 5 ml Dynabeads® (4.5 ... BerEP4 against the human epithelial ... molecule). Also available in ... 10e7 MNC in 1 ml ...
Biology Products: